search
Back to results

Dietary Interventions and Butyrate Production in Behçet's Patients

Primary Purpose

Behcet Syndrome

Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Oral butyrate
Vegetarian diet
Habitual diet
Sponsored by
Azienda Ospedaliero-Universitaria Careggi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Behcet Syndrome

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All patients affected by Behçet's disease

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Presence of diabetes mellitus
  • Presence of other immune-mediated diseases
  • Presence or history of cancer in the last 5 years
  • Presence of infectious diseases in the last 3 months
  • No antibiotic therapy in the last 3 months
  • No vegetarian or vegan diet
  • No intake of pro- or pre-biotics in the last 3 months

Sites / Locations

  • AOU Careggi

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

vegetarian diet

Habitual diet + oral butyrate

Habitual diet

Arm Description

vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products

habitual diet supplemented with 2.4g/day of oral butyrate

habitual diet without supplementation

Outcomes

Primary Outcome Measures

Evaluation of gut microbiota composition
Evaluation of butyrate production
For the extraction of SCFAs (and butyrate in particular) the method described in Schnorr et al. will be follow" [Schnorr SL, Candela M, Rampelli S, Centanni M, Consolandi C, Basaglia G,et al. Gut microbiome of the Hadza hunter-gatherers. Nat Commun 2014;5:3654]
Complete blood count
composite score
Lipid variables
composite score taking into account the levels of: total cholesterol, low density lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL), triglycerides
Glycemic profile
composite score taking into account the levels of : glucose, insulin, glycated hemoglobin (HbA1C), HOMA index
Vitamin profile
composite score, taking into account the levels of: vitamin B12, folic acid, vitamin D
Liver function tests
composite score taking into account the levels of: aspartate aminotransferase (AST), alanine transaminase (ALT), gammaglutamyl transferase (GGT), alkaline phosphatase (ALP), albumin, prealbumin
Kidney function tests
composite score taking into account the levels of : serum creatinine, urea, uric acid
Mineral profile
composite score taking into account the levels of: sodium, potassium, magnesium, calcium
Iron metabolism
composite score taking into account the levels of: iron, ferritin
Thyroid function
measurement of TSH levels
Inflammatory markers
composite score taking into account the levels of: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), fibrinogen, serum amyloid A (SAA)
Serology for celiac disease
composite score taking into account the levels of: IgA, anti-transglutaminase antibodies (IgA), anti endomysium antibodies (IgA)
Circulating levels of inflammatory cytokines
composite score
Oxidative stress markers
composite score

Secondary Outcome Measures

Evaluation Behçet's symptoms frequency and severity
Participants are asked to complete a questionnaire, which will assess Behçet's symptoms frequency and severity.

Full Information

First Posted
August 31, 2017
Last Updated
January 27, 2020
Sponsor
Azienda Ospedaliero-Universitaria Careggi
search

1. Study Identification

Unique Protocol Identification Number
NCT03274648
Brief Title
Dietary Interventions and Butyrate Production in Behçet's Patients
Official Title
Therapeutic Modulation of Butyrate Production in Behçet's Patients: a Dietary Intervention Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2020
Overall Recruitment Status
Completed
Study Start Date
September 27, 2017 (Actual)
Primary Completion Date
May 1, 2019 (Actual)
Study Completion Date
July 5, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Azienda Ospedaliero-Universitaria Careggi

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A dietary intervention trial will be performed on patients affected by Behçet's syndrome. Three different diets will be compared, analyzing their effects on the gut microbiota composition, on endogenous butyrate production and on the general symptoms in Behçet's patients.
Detailed Description
A dietary intervention trial will be conducted with the use of three different diets in order to compare the effects of these diets on the gut microbiota composition, on endogenous butyrate production and on the general symptoms in Behçet's patients. The study will be a randomized, open trial designed to test whether a vegetarian diet or an habitual diet supplemented with oral butyrate would benefit the butyrate production, the gut microbiota composition and the general symptoms of Behçet's patients, compared with the habitual diet. The study will involve 30 subjects with Behçet syndrome. Patients will be randomly assigned to follow a 3-months isocaloric dietary profile with either: vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products habitual diet supplemented with 2.4g/day of oral butyrate habitual diet without supplementation At the baseline visit, subjects will be educated about the aims and methods of the clinical trial and will sign their informed consent form. Anthropometric measurements, body composition, and blood and stool sampling will be obtained from each participant at the beginning and at the end of the intervention period. All subjects will be examined between 07.00 and 09.30 hours after a 12 h fasting period. The following parameters will be analyzed both at the beginning and at the end of the intervention period: Complete blood count Lipid variables - total cholesterol, low density lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL), triglycerides Glycemic profile - glucose, insulin, glycated hemoglobin (HbA1C), HOMA index Liver function tests - aspartate aminotransferase (AST), alanine transaminase (ALT), gammaglutamyl transferase (GGT), alkaline phosphatase (ALP), albumin, prealbumin Kidney function tests - serum creatinine, urea, uric acid Mineral profile - sodium, potassium, magnesium, calcium Iron metabolism - iron, ferritin Vitamin profile - vitamin B12, folic acid, vitamin D Thyroid function - TSH Inflammatory markers - erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), fibrinogen, serum amyloid A (SAA) Serology for celiac disease - IgA, anti-transglutaminase antibodies (IgA), anti endomysium antibodies (IgA) Circulating levels of inflammatory cytokines Oxidative stress markers Gut microbiota composition Butyrate production At the beginning and at the end of the intervention period, participants will be asked to complete a questionnaire, which will assess Behçet's symptoms frequency and severity. In addition, participants will be contacted by phone to complete a 24-hours recall in order to test the adherence to diets they have been assigned to.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Behcet Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Behçet's will be assigned to one of the following treatments: vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products habitual diet supplemented with 2.4g/day of oral butyrate habitual diet without supplementation
Masking
None (Open Label)
Allocation
Randomized
Enrollment
17 (Actual)

8. Arms, Groups, and Interventions

Arm Title
vegetarian diet
Arm Type
Experimental
Arm Description
vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
Arm Title
Habitual diet + oral butyrate
Arm Type
Experimental
Arm Description
habitual diet supplemented with 2.4g/day of oral butyrate
Arm Title
Habitual diet
Arm Type
Active Comparator
Arm Description
habitual diet without supplementation
Intervention Type
Dietary Supplement
Intervention Name(s)
Oral butyrate
Intervention Description
Patients follow the habitual diet supplemented with 2.4g/day of oral butyrate
Intervention Type
Dietary Supplement
Intervention Name(s)
Vegetarian diet
Intervention Description
Patients follow a vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
Intervention Type
Dietary Supplement
Intervention Name(s)
Habitual diet
Intervention Description
Patients follow the habitual diet
Primary Outcome Measure Information:
Title
Evaluation of gut microbiota composition
Time Frame
0-3 months
Title
Evaluation of butyrate production
Description
For the extraction of SCFAs (and butyrate in particular) the method described in Schnorr et al. will be follow" [Schnorr SL, Candela M, Rampelli S, Centanni M, Consolandi C, Basaglia G,et al. Gut microbiome of the Hadza hunter-gatherers. Nat Commun 2014;5:3654]
Time Frame
0-3 months
Title
Complete blood count
Description
composite score
Time Frame
0-3 months
Title
Lipid variables
Description
composite score taking into account the levels of: total cholesterol, low density lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL), triglycerides
Time Frame
0-3 months
Title
Glycemic profile
Description
composite score taking into account the levels of : glucose, insulin, glycated hemoglobin (HbA1C), HOMA index
Time Frame
0-3 months
Title
Vitamin profile
Description
composite score, taking into account the levels of: vitamin B12, folic acid, vitamin D
Time Frame
0-3 months
Title
Liver function tests
Description
composite score taking into account the levels of: aspartate aminotransferase (AST), alanine transaminase (ALT), gammaglutamyl transferase (GGT), alkaline phosphatase (ALP), albumin, prealbumin
Time Frame
0-3 months
Title
Kidney function tests
Description
composite score taking into account the levels of : serum creatinine, urea, uric acid
Time Frame
0-3 months
Title
Mineral profile
Description
composite score taking into account the levels of: sodium, potassium, magnesium, calcium
Time Frame
0-3 months
Title
Iron metabolism
Description
composite score taking into account the levels of: iron, ferritin
Time Frame
0-3 months
Title
Thyroid function
Description
measurement of TSH levels
Time Frame
0-3 months
Title
Inflammatory markers
Description
composite score taking into account the levels of: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), fibrinogen, serum amyloid A (SAA)
Time Frame
0-3 months
Title
Serology for celiac disease
Description
composite score taking into account the levels of: IgA, anti-transglutaminase antibodies (IgA), anti endomysium antibodies (IgA)
Time Frame
0-3 months
Title
Circulating levels of inflammatory cytokines
Description
composite score
Time Frame
0-3 months
Title
Oxidative stress markers
Description
composite score
Time Frame
0-3 months
Secondary Outcome Measure Information:
Title
Evaluation Behçet's symptoms frequency and severity
Description
Participants are asked to complete a questionnaire, which will assess Behçet's symptoms frequency and severity.
Time Frame
0-3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All patients affected by Behçet's disease Exclusion Criteria: Pregnancy or breastfeeding Presence of diabetes mellitus Presence of other immune-mediated diseases Presence or history of cancer in the last 5 years Presence of infectious diseases in the last 3 months No antibiotic therapy in the last 3 months No vegetarian or vegan diet No intake of pro- or pre-biotics in the last 3 months
Facility Information:
Facility Name
AOU Careggi
City
Florence
ZIP/Postal Code
50134
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
IPD will not be shared
Citations:
PubMed Identifier
25852265
Citation
Skef W, Hamilton MJ, Arayssi T. Gastrointestinal Behcet's disease: a review. World J Gastroenterol. 2015 Apr 7;21(13):3801-12. doi: 10.3748/wjg.v21.i13.3801.
Results Reference
background
PubMed Identifier
25435420
Citation
Consolandi C, Turroni S, Emmi G, Severgnini M, Fiori J, Peano C, Biagi E, Grassi A, Rampelli S, Silvestri E, Centanni M, Cianchi F, Gotti R, Emmi L, Brigidi P, Bizzaro N, De Bellis G, Prisco D, Candela M, D'Elios MM. Behcet's syndrome patients exhibit specific microbiome signature. Autoimmun Rev. 2015 Apr;14(4):269-76. doi: 10.1016/j.autrev.2014.11.009. Epub 2014 Nov 27.
Results Reference
background
PubMed Identifier
24898225
Citation
Wong JM. Gut microbiota and cardiometabolic outcomes: influence of dietary patterns and their associated components. Am J Clin Nutr. 2014 Jul;100 Suppl 1:369S-77S. doi: 10.3945/ajcn.113.071639. Epub 2014 Jun 4.
Results Reference
background

Learn more about this trial

Dietary Interventions and Butyrate Production in Behçet's Patients

We'll reach out to this number within 24 hrs